高リスク患者の早期の術後の吐き気を予防する第三の抗嘔吐剤としての低用量レミサゾラムの有効性: ランダム化比較試験
PubMedで要約を見る
まとめ
この要約は機械生成です。低用量レミザロラムは,手術後の吐き気と嘔吐 (PONV) を24時間後に防ぐことができなかった. しかし,麻酔後のケアユニット (PACU) で6時間後に吐き気とめまいを軽減しました.
科学分野
- 麻酔科
- 薬理学について
背景
- 術後の吐き気 (PONV) は,全身麻酔の一般的な合併症です.
- 現在のガイドラインでは,高リスクの患者に少なくとも3つの予防的抗嘔吐剤を推奨しています.
- ミダゾラムのサブ催眠用投与は,嘔吐抑制効果を示した.
研究 の 目的
- PONVの第三の予防抗嘔吐剤として,超短期間作用のベンゾジアゼピンであるレミザーラムの有効性を調査する.
- 一般麻酔を受けた患者の低目標用量でのレミマゾラムの評価.
主な方法
- 108人の患者を対象としたランダム化試験です.
- 患者は麻酔維持のためにセボフルランを投与した.
- レミマゾラム群 (R群) は追加の低用量レミマゾラム注入 (0. 3 mg/ kg/ hr) を受け,対照群 (C群) は受けなかった.
- すべての患者はラモセトロンとデキサメトソンを標準的な抗嘔吐剤として投与された.
- 評価されたアウトカムには,PONVの発生率と重症度,回復の質,および術後24時間の痛みのスコアが含まれていました.
主要な成果
- 24時間後のPONVの総発生率や重症度は,グループによって有意な差異はありません.
- Rグループは,Cグループと比較して,手術後6時間後に嘔吐の発生率が有意に低かった (31. 5% vs 52. 9%).
- グループCは,グループRと比較してPACUでめまいが有意に高かった (19. 6%対1. 9%).
結論
- 低用量レミザロラムの輸注は,24時間後にPONVの全体的な発生率を減少させなかった.
- レミマゾラムは,PACUで6時間後に吐き気が減り,めまいが減った.
- PONV予防におけるレミザロラムの最適な用量または患者の選択をさらに研究することが可能である.
関連する概念動画
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...

